@article{oai:repository.lib.tottori-u.ac.jp:00004736,
 author = {Sugihara, Takaaki and Nagahara, Takakazu and Okano, Jun-ichi and Fujioka, Youhei and Yamamoto, Kazuhiro and Isomoto, Hajime and Ikeda, Suguru and Hoshino, Yoshiki and Matsuki, Yukako and Kitao, Sonoko},
 issue = {3},
 journal = {Yonago Acta Medica, Yonago Acta Medica},
 month = {Aug},
 note = {[Background] Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome, which can progress to liver cirrhosis. Standard medication has not been established. Pemafibrate is a selective peroxisome proliferatoractivated receptor (PPAR) α modulator. We retrospectively evaluated the efficacy of pemafibrate in patients with NAFLD. [Methods] We retrospectively enrolled 17 patients (ten men, seven women; median age, 63 years; range, 27?81 years). They were all proven to have fatty liver through imaging and had little or no history of drinking (ethanol consumption of < 20 g/day for women and < 30 g/day for men). They were administered pemafibrate from October 2018 to June 2020. [Results] After administration, serum triglyceride (TG) tended to be decreased (300.5 ± 22.5 to 239.5 ± 34.3 mg/dL, P = 0.06). Serum high-density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol levels did not change. ALT was significantly decreased (-47.4%) for six months (57.5 ± 8.8 to 30.3 ± 5.8 U/L, P < 0.01). The values of serum GGT significantly decreased (-48.7%) for sixth months (63.9 ± 10.3 to 32.8 ± 6.6 U/L, P < 0.01). Aspartate aminotransferase (AST) to platelet ratio (APRI), a fibrosis marker, also was significantly decreased in the sixth month (0.7 ± 0.1 to 0.4 ± 0.1, P < 0.05). Body mass index (BMI) and hemoglobin A1c (HbA1c) showed no significant change. [Conclusion] Pemafibrate dramatically ameliorated the values of liver function tests and APRI in patients with NAFLD.},
 pages = {188--197},
 title = {Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease},
 volume = {63},
 year = {2020},
 yomi = {イケダ, スグル and スギハラ, タカアキ and ホシノ, ヨウヘイ and マツキ, ユカコ and ナガハラ, タカカズ and オカノ, ジュンイチ and キタオ, ソノコ and フジオカ, ヨウヘイ and ヤマモト, カズヒロ and イソモト, ハジメ and イケダ, スグル and ホシノ, ヨウヘイ and マツキ, ユカコ and キタオ, ソノコ}
}